Product Description
Mechanisms of Action: ADORA2 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Ocular,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Santen
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Glaucoma, Open-Angle|Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT01279083 | P2 |
Completed |
Hypertension|Glaucoma, Open-Angle |
2011-11-01 |